M
MERUS BV
NASDAQ: MRUS (Merus N.V.)
Kemas kini terakhir: semalam, 4:15AM41.85
-0.24 (-0.57%)
| Penutupan Terdahulu | 42.09 |
| Buka | 42.39 |
| Jumlah Dagangan | 723,520 |
| Purata Dagangan (3B) | 537,536 |
| Modal Pasaran | 2,865,205,504 |
| Harga / Jualan (P/S) | 73.33 |
| Harga / Buku (P/B) | 4.17 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Operasi (TTM) | -613.59% |
| EPS Cair (TTM) | -4.03 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.57% |
| Nisbah Semasa (MRQ) | 8.32 |
| Aliran Tunai Operasi (OCF TTM) | -155.52 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -109.10 M |
| Pulangan Atas Aset (ROA TTM) | -21.59% |
| Pulangan Atas Ekuiti (ROE TTM) | -44.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Merus N.V. | Menaik | Menaik |
AISkor Stockmoo
2.3
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 2.25 |
|
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 2.03% |
| % Dimiliki oleh Institusi | 105.66% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Commodore Capital Lp | 30 Sep 2024 | 3,350,000 |
| Lynx1 Capital Management Lp | 30 Sep 2024 | 1,793,866 |
| Holocene Advisors, Lp | 30 Sep 2024 | 1,637,988 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 111.00 (Guggenheim, 165.23%) | Beli |
| Median | 85.00 (103.11%) | |
| Rendah | 72.00 (UBS, 72.04%) | Beli |
| Purata | 87.17 (108.29%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 45.31 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 09 Dec 2024 | 97.00 (131.78%) | Beli | 43.74 |
| Needham | 09 Dec 2024 | 85.00 (103.11%) | Beli | 43.74 |
| 05 Dec 2024 | 85.00 (103.11%) | Beli | 43.86 | |
| Guggenheim | 05 Dec 2024 | 111.00 (165.23%) | Beli | 43.86 |
| 03 Dec 2024 | 109.00 (160.45%) | Beli | 46.21 | |
| HC Wainwright & Co. | 05 Dec 2024 | 85.00 (103.11%) | Beli | 43.86 |
| 02 Dec 2024 | 85.00 (103.11%) | Beli | 48.53 | |
| Goldman Sachs | 21 Nov 2024 | 73.00 (74.43%) | Beli | 44.36 |
| UBS | 24 Oct 2024 | 72.00 (72.04%) | Beli | 52.30 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |